Role of co‑inhibitory molecules in the treatment of psoriasis (Review)
- Authors:
- Yue Yao
- Linxi Zeng
- Xin Huang
- Jinfang Zhang
- Guoqiang Zhang
- Ling Wang
-
Affiliations: Department of Dermatology, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei 050031, P.R. China, Department of Orthopedic Oncology, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China - Published online on: March 19, 2024 https://doi.org/10.3892/etm.2024.12497
- Article Number: 209
This article is mentioned in:
Abstract
 |
|
Cai Y, Fleming C and Yan J: New insights of T cells in the pathogenesis of psoriasis. Cell Mol Immunol. 9:302–309. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Kim J and Krueger JG: Highly effective new treatments for psoriasis target the IL-23/Type 17 T cell autoimmune axis. Annu Rev Med. 68:255–269. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Lowes MA, Russell CB, Martin DA, Towne JE and Krueger JG: The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol. 34:174–181. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Hawkes JE, Chan TC and Krueger JG: Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 140:645–653. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Zhang Q and Vignali DA: Co-stimulatory and co-inhibitory pathways in autoimmunity. Immunity. 44:1034–1051. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Mahoney KM, Rennert PD and Freeman GJ: Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 14:561–584. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Schnell A, Bod L, Madi A and Kuchroo VK: The yin and yang of co-inhibitory receptors: Toward anti-tumor immunity without autoimmunity. Cell Res. 30:285–299. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Reynolds J, Sando GS, Marsh OB, Salama AD, Evans DJ, Cook HT and Pusey CD: Stimulation of the PD-1/PDL-1 T-cell co-inhibitory pathway is effective in treatment of experimental autoimmune glomerulonephritis. Nephrol Dial Transplant. 27:1343–1350. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Ibañez-Vega J, Vilchez C, Jimenez K, Guevara C, Burgos PI and Naves R: Cellular and molecular regulation of the programmed death-1/programmed death ligand system and its role in multiple sclerosis and other autoimmune diseases. J Autoimmun. 123(102702)2021.PubMed/NCBI View Article : Google Scholar | |
|
Kurita M, Yoshihara Y, Ishiuji Y, Chihara M, Ishiji T, Asahina A and Yanaba K: Expression of T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain on CD4(+) T cells in patients with atopic dermatitis. J Dermatol. 46:37–42. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Du Y, Nie L, Xu L, Wu X, Zhang S and Xue J: Serum levels of soluble programmed death-1 (sPD-1) and soluble programmed death ligand 1(sPD-L1) in systemic lupus erythematosus: Association with activity and severity. Scand J Immunol. 92(e12884)2020.PubMed/NCBI View Article : Google Scholar | |
|
Greb JE, Goldminz AM, Elder JT, Lebwohl MG, Gladman DD, Wu JJ, Mehta NN, Finlay AY and Gottlieb AB: Psoriasis. Nat Rev Dis Primers. 2(16082)2016.PubMed/NCBI View Article : Google Scholar | |
|
Lee HJ and Kim M: Challenges and future trends in the treatment of psoriasis. Int J Mol Sci. 24(13313)2023.PubMed/NCBI View Article : Google Scholar | |
|
Lin X and Huang T: Co-signaling molecules in psoriasis pathogenesis: Implications for targeted therapy. Hum Immunol. 76:95–101. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Salama AK and Hodi FS: Cytotoxic T-lymphocyte-associated antigen-4. Clin Cancer Res. 17:4622–4628. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Suárez-Fariñas M, Li K, Fuentes-Duculan J, Hayden K, Brodmerkel C and Krueger JG: Expanding the psoriasis disease profile: Interrogation of the skin and serum of patients with moderate-to-severe psoriasis. J Invest Dermatol. 132:2552–2564. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Liu P, He Y, Wang H, Kuang Y, Chen W, Li J, Chen M, Zhang J, Su J, Zhao S, et al: The expression of mCTLA-4 in skin lesion inversely correlates with the severity of psoriasis. J Dermatol Sci. 89:233–240. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Wang K, Zhu Q, Lu Y, Lu H, Zhang F, Wang X and Fan Y: CTLA-4 +49 G/A polymorphism confers autoimmune disease risk: An updated meta-analysis. Genet Test Mol Biomarkers. 21:222–227. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Wang XB, Zhao X, Giscombe R and Lefvert AK: A CTLA-4 gene polymorphism at position -318 in the promoter region affects the expression of protein. Genes Immun. 3:233–234. 2002.PubMed/NCBI View Article : Google Scholar | |
|
Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, Rainbow DB, Hunter KM, Smith AN, Di Genova G, et al: Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature. 423:506–511. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Pérez-García A, Osca G, Bosch-Vizcaya A, Kelleher N, Santos NY, Rodríguez R, González Y, Roncero JM, Coll R, Serrando M, et al: Kinetics of the CTLA-4 isoforms expression after T-lymphocyte activation and role of the promoter polymorphisms on CTLA-4 gene transcription. Hum Immunol. 74:1219–1224. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Dursun HG, Yılmaz HO, Dursun R and Kulaksızoğlu S: Association of Cytotoxic T Lymphocyte Antigen-4 gene polymorphisms with psoriasis vulgaris: A case-control study in turkish population. J Immunol Res. 2018(1643906)2018.PubMed/NCBI View Article : Google Scholar | |
|
Abrams JR, Lebwohl MG, Guzzo CA, Jegasothy BV, Goldfarb MT, Goffe BS, Menter A, Lowe NJ, Krueger G, Brown MJ, et al: CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest. 103:1243–1252. 1999.PubMed/NCBI View Article : Google Scholar | |
|
Abrams JR, Kelley SL, Hayes E, Kikuchi T, Brown MJ, Kang S, Lebwohl MG, Guzzo CA, Jegasothy BV, Linsley PS and Krueger JG: Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med. 192:681–694. 2000.PubMed/NCBI View Article : Google Scholar | |
|
Altmeyer MD, Kerisit KG and Boh EE: Therapeutic hotline. Abatacept: Our experience of use in two patients with refractory psoriasis and psoriatic arthritis. Dermatol Ther. 24:287–290. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, Dubreuil M, Dunham J, Husni ME, Kenny S, et al: Special Article: 2018 American College of Rheumatology/National psoriasis foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 71:5–32. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Mease PJ, Gottlieb AB, van der Heijde D, FitzGerald O, Johnsen A, Nys M, Banerjee S and Gladman DD: Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Ann Rheum Dis. 76:1550–1558. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Liu S, Xu J and Wu J: The role of co-signaling molecules in psoriasis and their implications for targeted treatment. Front Pharmacol. 12(717042)2021.PubMed/NCBI View Article : Google Scholar | |
|
Harris KM, Smilek DE, Byron M, Lim N, Barry WT, McNamara J, Garcet S, Konrad RJ, Stengelin M, Bathala P, et al: Effect of costimulatory blockade with abatacept after ustekinumab withdrawal in patients with moderate to severe plaque psoriasis: The PAUSE Randomized clinical trial. JAMA Dermatol. 157:1306–1315. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Sharpe AH and Pauken KE: The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 18:153–167. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Khatery BH, Shaker OG, El-Tahlawi S, Abd-Elrahim TA, Fawzi M, Ali EM and Mohammed MH: Are programmed cell death protein-1 and Angiopoietins-2 effective biomarkers for detection the severity of psoriatic patients? J Cosmet Dermatol. 21:5208–5214. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Jung CJ, Yang HJ, Bang SH, Lee WJ, Won CH, Lee MW, Song Y and Chang SE: Clinicoprognostic and histopathological features of guttate and plaque psoriasis based on PD-1 expression. J Clin Med. 10(5200)2021.PubMed/NCBI View Article : Google Scholar | |
|
Kim DS, Je JH, Kim SH, Shin D, Kim TG, Kim DY, Kim SM and Lee MG: Programmed death-ligand 1, 2 expressions are decreased in the psoriatic epidermis. Arch Dermatol Res. 307:531–538. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Keir ME, Butte MJ, Freeman GJ and Sharpe AH: PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 26:677–704. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Tanaka R, Ichimura Y, Kubota N, Saito A, Nakamura Y, Ishitsuka Y, Watanabe R, Fujisawa Y, Mizuno S, Takahashi S, et al: Differential Involvement of Programmed Cell Death Ligands in Skin Immune Responses. J Invest Dermatol. 142:145–154.e8. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Bonigen J, Raynaud-Donzel C, Hureaux J, Kramkimel N, Blom A, Jeudy G, Breton AL, Hubiche T, Bedane C, Legoupil D, et al: Anti-PD1-induced psoriasis: A study of 21 patients. J Eur Acad Dermatol Venereol. 31:e254–e257. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Sibaud V, Meyer N, Lamant L, Vigarios E, Mazieres J and Delord JP: Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Curr Opin Oncol. 28:254–263. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Voudouri D, Nikolaou V, Laschos K, Charpidou A, Soupos N, Triantafyllopoulou I, Panoutsopoulou I, Aravantinos G, Syrigos K and Stratigos A: Anti-PD1/PDL1 induced psoriasis. Curr Probl Cancer. 41:407–412. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Murata S, Kaneko S, Harada Y, Aoi N and Morita E: Case of de novo psoriasis possibly triggered by nivolumab. J Dermatol. 44:99–100. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Sanlorenzo M, Vujic I, Daud A, Algazi A, Gubens M, Luna SA, Lin K, Quaglino P, Rappersberger K and Ortiz-Urda S: Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol. 151:1206–1212. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, Papp K, Spelman L, Toth D, Kerdel F, et al: Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 373:1318–1328. 2015.PubMed/NCBI View Article : Google Scholar | |
|
McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, Brodmerkel C, Li S, Wang Y, Mendelsohn AM, et al: Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 382:780–789. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Kim JH, Choi YJ, Lee BH, Song MY, Ban CY, Kim J, Park J, Kim SE, Kim TG, Park SH, et al: Programmed cell death ligand 1 alleviates psoriatic inflammation by suppressing IL-17A production from programmed cell death 1-high T cells. J Allergy Clin Immunol. 137:1466–1476.e3. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A and Gottlieb AB: Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 349:2014–2022. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Peng S, Cao M, Sun X, Zhou Y, Chen CY, Ma T, Li H, Li B, Zhu B and Li X: Recombinant programmed cell death 1 inhibits psoriatic inflammation in imiquimod-treated mice. Int J Mol Med. 46:869–879. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Xu F, Fei Z, Dai H, Xu J, Fan Q, Shen S, Zhang Y, Ma Q, Chu J, Peng F, et al: Mesenchymal stem cell-derived extracellular vesicles with high PD-L1 expression for autoimmune diseases treatment. Adv Mater. 34(e2106265)2022.PubMed/NCBI View Article : Google Scholar | |
|
Anderson AC, Joller N and Kuchroo VK: Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation. Immunity. 44:989–1004. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Hemon P, Jean-Louis F, Ramgolam K, Brignone C, Viguier M, Bachelez H, Triebel F, Charron D, Aoudjit F, Al-Daccak R and Michel L: MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis. J Immunol. 186:5173–5183. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Kouo T, Huang L, Pucsek AB, Cao M, Solt S, Armstrong T and Jaffee E: Galectin-3 Shapes antitumor immune responses by suppressing CD8+ T Cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells. Cancer Immunol Res. 3:412–423. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Xu F, Liu J, Liu D, Liu B, Wang M, Hu Z, Du X, Tang L and He F: LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses. Cancer Res. 74:3418–3428. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Mao X, Ou MT, Karuppagounder SS, Kam TI, Yin X, Xiong Y, Ge P, Umanah GE, Brahmachari S, Shin JH, et al: Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science. 353(aah3374)2016.PubMed/NCBI View Article : Google Scholar | |
|
Wang J, Sanmamed MF, Datar I, Su TT, Ji L, Sun J, Chen L, Chen Y, Zhu G, Yin W, et al: Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3. Cell. 176:334–347.e12. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Kim J, Lee J, Gonzalez J, Fuentes-Duculan J, Garcet S and Krueger JG: Proportion of CD4(+)CD49b(+)LAG-3(+) type 1 regulatory T cells in the blood of psoriasis patients inversely correlates with psoriasis area and severity index. J Invest Dermatol. 138:2669–2672. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Gertel S, Polachek A, Furer V, Levartovsky D and Elkayam O: CD4(+) LAG-3(+) T cells are decreased in active psoriatic arthritis patients and their restoration in vitro is mediated by TNF inhibitors. Clin Exp Immunol. 206:173–183. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Castelli C, Triebel F, Rivoltini L and Camisaschi C: Lymphocyte activation gene-3 (LAG-3, CD223) in plasmacytoid dendritic cells (pDCs): A molecular target for the restoration of active antitumor immunity. Oncoimmunology. 3(e967146)2014.PubMed/NCBI View Article : Google Scholar | |
|
Ellis J, J B Marks D, Srinivasan N, Barrett C, Hopkins TG, Richards A, Fuhr R, Albayaty M, Coenen M, Liefaard L, et al: Depletion of LAG-3(+) T cells translated to pharmacology and improvement in psoriasis disease activity: A phase I randomized study of mAb GSK2831781. Clin Pharmacol Ther. 109:1293–1303. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Wolf Y, Anderson AC and Kuchroo VK: TIM3 comes of age as an inhibitory receptor. Nat Rev Immunol. 20:173–185. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Kanai Y, Satoh T, Igawa K and Yokozeki H: Impaired expression of Tim-3 on Th17 and Th1 cells in psoriasis. Acta Derm Venereol. 92:367–371. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Igawa K, Satoh T, Hirashima M and Yokozeki H: Regulatory mechanisms of galectin-9 and eotaxin-3 synthesis in epidermal keratinocytes: Possible involvement of galectin-9 in dermal eosinophilia of Th1-polarized skin inflammation. Allergy. 61:1385–1391. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Nishi N, Itoh A, Fujiyama A, Yoshida N, Araya S, Hirashima M, Shoji H and Nakamura T: Development of highly stable galectins: Truncation of the linker peptide confers protease-resistance on tandem-repeat type galectins. FEBS Lett. 579:2058–2064. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Niwa H, Satoh T, Matsushima Y, Hosoya K, Saeki K, Niki T, Hirashima M and Yokozeki H: Stable form of galectin-9, a Tim-3 ligand, inhibits contact hypersensitivity and psoriatic reactions: A potent therapeutic tool for Th1- and/or Th17-mediated skin inflammation. Clin Immunol. 132:184–194. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Mease P, Genovese MC, Gladstein G, Kivitz AJ, Ritchlin C, Tak PP, Wollenhaupt J, Bahary O, Becker JC, Kelly S, et al: Abatacept in the treatment of patients with psoriatic arthritis: Results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum. 63:939–948. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Strand V, Alemao E, Lehman T, Johnsen A, Banerjee S, Ahmad HA and Mease PJ: Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: Results from a phase 3 trial. Arthritis Res Ther. 20(269)2018.PubMed/NCBI View Article : Google Scholar | |
|
Imai Y, Ayithan N, Wu X, Yuan Y, Wang L and Hwang ST: Cutting Edge: PD-1 regulates imiquimod-induced psoriasiform dermatitis through inhibition of IL-17A expression by innate γδ-Low T Cells. J Immunol. 195:421–425. 2015.PubMed/NCBI View Article : Google Scholar |
